<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Even after recently agreeing to shell out $11.5 billion to acquire Acceleron Pharma Inc. ( XLRN , Financial), Merck & Co. Inc. ( MRK , Financial) says it’s not done in its quest for deals aimed at diversifying its business. The more than $200 billion pharmaceutical giant wants to expand its offerings to soften the blow when its mega-blockbuster drug, Keytruda, loses patent protection around 2028, according to FiercePharma.
...read full article on GuruFocus
